INSIGHTS ON CLINICAL TRIAL DESIGN

• Simplifying ePRO Data Collection

  The Bring Your Own Device (BYOD) model, supported by Trialkit, is an innovative approach in clinical trials that allows participants to use personal smartphones or tablets for data collection.

• Demonstrating IDS Value With Time-Based Metrics

  Explore how leading IDS pharmacies are using remote monitoring workflows and digital accountability systems to improve accuracy, reduce site burden, and maintain audit readiness.

• Evolving IRT For Today's Trials: Flexibility, Site Experience, And Integrated Workflow

  Interactive Response Technology is evolving beyond traditional randomization and trial supply management to help guide protocol workflows in increasingly complex studies.

• Phase 1 Trial In Painful Diabetic Peripheral Neuropathy

  A complex Phase 1 neuropathy study with overnight stays achieved full enrollment and retention through careful planning, strong participant engagement, and disciplined operational execution.

• From Months To Hours: MMC Medical's EDC Revolution

  3/31/2026

  Learn how a specialized CRO reduced study build times by 95%. Discover strategies for template reusability and flexible resource scaling to accelerate early-stage medical device validation.

• Medical Insight's Role In Early-Phase Clinical Development

  1/6/2026

  Medical insight reduces risk, strengthens protocols, and accelerates timelines — enhancing safety, feasibility, and collaboration for successful trials and reliable outcomes.

• How To Reduce Eligibility Risk And Prevent Protocol Deviations

  3/18/2026

  Eliminate enrollment-based protocol deviations and align with the latest FDA guidance by implementing a centralized, technology-enabled eligibility review to safeguard trial integrity.

• Accelerating Enrollment And Upholding Quality In Complex Oncology Trials

  5/5/2026

  Real-world oncology trials reveal how fast physician engagement, hands-on biomarker management, and adaptive enrollment shorten timelines, reach first-patient milestones, and preserve data quality.

• De-Risking Early-Stage Biotech: Turning Vision Into Venture Capital

  9/3/2025

  For early-stage biotech companies, transforming a scientific breakthrough into an investable asset requires more than compelling data—it requires a clear product vision.